• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Aslan Pharmaceuticals, National Cancer Center Singapore collaborate

Aslan Pharmaceuticals, National Cancer Center Singapore collaborate

July 22, 2015
CenterWatch Staff

Aslan Pharmaceuticals, an oncology focused biotechnology company, and National Cancer Center Singapore (NCCS) have signed a Memorandum of Understanding (MOU) that will further enhance the study of novel therapeutic agents for the treatment of gastric cancer, hepatocellular carcinoma (liver) and cholangiocarcinoma (bile duct), three common forms of gastrointestinal (GI) cancers that are particularly prevalent in Asia. 

Aslan and NCCS will initiate a number of collaborative projects focused on increasing the understanding of novel combinations of known therapeutic agents, including Aslan’s clinical development programs (ASLAN001 and ASLAN002), through preclinical research involving patient-derived cell lines and xenograft models. In addition, the parties will jointly conduct clinical trials studying novel treatments for Asia-prevalent cancers. 

To encourage a broader clinical understanding of gastric cancers in the region, Aslan and NCCS will host a series of disease symposiums in Asia. The symposiums, which will include a dedicated biannual cholangiocarcinoma symposium in Singapore, will bring together GI cancer scientists and clinicians to share research breakthroughs and facilitate knowledge exchange. 

Overall, GI cancers are responsible for more deaths than any other types of cancer. Worldwide, gastric cancer has one of the highest incidence rates, with 952,000 new cases diagnosed in 2012. In Asia, gastric cancer is the third most common cancer after breast and liver, and is the second most common cause of cancer deaths in Asia. There currently are no effective treatments approved for cholangiocarcinoma, a rare tumor comprising of only 3% of GI tumors, but with geographically heterogeneous prevalence whereby the highest rates are in Asia, notably Southeast Asia. 

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing